Najat Khan - 03 Feb 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Chief R&D Commercial Officer, Director
Signature: /s/ Kyle Nelson, attorney-in-fact
Issuer symbol: RXRX
Transactions as of: 03 Feb 2025
Net transactions value: -$19,959
Form type: 4
Filing time: 05 Feb 2025, 16:50:30 UTC
Previous filing: 05 Aug 2024
Next filing: 19 May 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Award	$0	+210,113	+42%	$0.000000	707,085	03 Feb 2025	Direct	F1
transaction	RXRX	Class A Common Stock	Award	$0	+8,049	+1.1%	$0.000000	715,134	03 Feb 2025	Direct	F2
transaction	RXRX	Class A Common Stock	Tax liability	$19,959	-2,753	-0.38%	$7.25	712,381	03 Feb 2025	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Award	$0	+420,226		$0.000000	420,226	03 Feb 2025	Class A Common Stock	420,226	$7.25	Direct	F4
holding	RXRX	Stock Option (Right to Buy)						993,944	03 Feb 2025	Class A Common Stock	0	$7.34	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2025 and every three months thereafter.
F2	This RSU vested immediately upon the grant date.
F3	Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F4	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F5	This option vests as to one fourth (1/4th) of the shares subject to the option on July 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date.